Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Picard Medical, Inc. ( (PMI) ) has provided an update.
On January 13, 2026, Picard Medical published a new investor presentation outlining SynCardia’s position as a market leader in total artificial heart technology and detailing the company’s mission to pioneer heart replacement as an alternative to transplantation amid a persistent shortage of donor hearts. The materials highlight SynCardia’s unique regulatory status, global clinical footprint and commercial strategy, while also providing an updated snapshot of Picard Medical’s market capitalization, share statistics and management structure, signaling an effort to sharpen investor communications and reinforce the company’s growth ambitions in the advanced cardiac device segment.
The most recent analyst rating on (PMI) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Picard Medical, Inc. stock, see the PMI Stock Forecast page.
Spark’s Take on PMI Stock
According to Spark, TipRanks’ AI Analyst, PMI is a Neutral.
The score is held down primarily by very weak financial performance (large losses and sustained cash burn) and bearish technicals (below key moving averages with negative MACD). Support comes from improved TTM balance-sheet leverage and positive corporate developments, including new secured financing and product milestones, but these are not yet enough to offset the current profitability and funding-risk profile.
To see Spark’s full report on PMI stock, click here.
More about Picard Medical, Inc.
Picard Medical, Inc., listed on the NYSE American under ticker PMI, is the parent company of SynCardia Systems, a medical device maker focused on total artificial heart (TAH) technology as an alternative to heart transplantation. SynCardia’s Total Artificial Heart is currently the only commercially available TAH approved by both the U.S. Food and Drug Administration and Health Canada, with more than 2,100 implants performed at hospitals in 27 countries, and the business is targeting scalable growth through a mix of direct sales and distributor partnerships, supported by an experienced leadership team with deep MedTech, engineering and financial expertise.
Average Trading Volume: 1,917,466
Technical Sentiment Signal: Strong Sell
See more insights into PMI stock on TipRanks’ Stock Analysis page.